Boehringer Ingelheim, one of the world’s 20 leading pharmaceutical companies, has received the Pharmaceutical Brand of the Year – New Launch 2013 award for its most appreciated product Trajenta at the Frost & Sullivan India Healthcare Excellence Awards 2013 in Mumbai. Trajenta is an original research product of Boehringer Ingelheim launched in 2012 post robust clinical trial programmes conducted in India, United States, European Union and Japan among other countries.
Trajenta is a first-of-its-kind anti-diabetic drug with a one-dose-for-all solution for diabetics in India, where dose adjustment is not required irrespective of any degree of renal or hepatic dysfunction in the patient. The coveted Frost & Sullivan India Healthcare Excellence Awards commended Boehringer Ingelheim for superior planning and execution of the product launch, distribution strategy, technological innovation and customer services.
Congratulating Boehringer Ingelheim on the award, Jayant Singh, associate director, Pharma and Medical Technology, Healthcare Practice, Frost & Sullivan, said, “Trajenta has established itself in a short period of time in the highly competitive diabetes market. Though being a late entrant in its drug class, the brand achieving a substantial market share within nine months of its launch, speaks volumes for its success. The brand has received tremendous response from the treating physicians due to its efficacy and safety profile and has exhibited highest sales and growth rate amongst the innovative brands launched in FY 2012 which has led to the brand being recognized as the best launch of the year.”
Commenting on the award, Sharad Tyagi, managing director, Boehringer Ingelheim (BI) India, said, “This award is a recognition of Boehringer’s ongoing commitment to address patients’ unmet needs amidst the growing Indian diabetes pandemic. This appreciation marks an important milestone in our journey and will significantly inspire our robust and unique alliance with Lilly to serve many more patients and play a leading role in fighting diabetes in India.”
Trajenta emerged as one of the best-in-class drug for treatment of type 2 diabetes owing to the exemplary efficacy and safety profile and the robust field force, gaining a substantial market share of 10.6 per cent (June MAT, 2013).The product is widely marketed by BI-Lilly alliance and is available on prescription in pharmacy outlets across the country.